Has Michael Yang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $89,606 in general payments to Michael Yang, MD across 414 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Yang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Yang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Yang, MD

Pain Medicine · Santa Rosa, CANPI 1063665438

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Nevro Corp. at 55.4% of the total. Reporting peaked in 2019 at $49,077 and has fallen 96.8% since, to $1,592 in 2025. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,606in general payments, 2019–2025

Across 414 payments — averaging $216.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Nevro Corp.$50K
Boston Scientific$37K
Abbott$689
Medtronic$673
Eli Lilly$441
Saluda Medical Americas, Inc.$369
plus $1K from 11 others

$576,436in research payments, 2019–2025

Across 214 payments — averaging $2693.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boston Scientific$423K
Nevro Corp.$144K
Saluda Medical Americas, Inc.$9K
Flowonix Medical Incorporated$500

What the payments were for

Consulting fees$19,87522%
Speaking & faculty fees$50,66657%
Travel & lodging$7,8969%
Food & beverage$10,34012%
Education$8281%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Nevro Corp.	135	$49,606
Boston Scientific	168	$36,689
Abbott	25	$689
Medtronic	22	$673
Eli Lilly	19	$441
Saluda Medical Americas, Inc.	10	$369
Relievant Medsystems, Inc.	3	$335
Biotronik NRO, Inc.	4	$267
Painteq LLC	1	$119
Pfizer	15	$116
Flowonix Medical Incorporated	2	$87
Scilex Pharmaceuticals Inc.	4	$78
AbbVie	2	$44
Globus Medical	1	$30
Bioventus LLC	1	$21
Kaleo, Inc.	1	$21
Johnson & Johnson	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Senza Spinal Cord Stimulation System$31,992
SPECTRA WAVEWRITER$16,874
Omnia$15,004
GENERAL PAIN MANAGEMENT$7,516
WaveWriter Alpha Prime 16$2,125
Intracept$1,501
GENERAL - THERAPIES$1,488
Senza$449
Evoke$150
SYNCHROMEDII$145
Prospera$123
PAINTEQ$119

How this compares

$89,606 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California →

Medicare billing

Part B allowed, 2024

$241,205

Medicare patients

504

Services billed

1,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	70	$1,542
Oxycodone Hcl	54	$1,489
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	55	$1,235
Gabapentin	85	$1,110
Morphine Sulfate ErMorphine Sulfate	12	$226
Cephalexin	24	$123
Tramadol Hcl	19	$79

Paid to pharmacies, not to this prescriber.

Other pain medicine in Santa Rosa

Jason PopeSanta Rosa$2.1M
Ramana NaiduLarkspur$1.4M
Foead GeulaStudio City$1.3M
Krishnan ChakravarthyTemecula$1.3M
Kasra AmirdelfanWalnut Creek$783K
Eric GrigsbyNapa$499K
Jacqueline WeisbeinNapa$494K
Gerald SacksSanta Monica$389K
Samir ShethRoseville$356K
Einar OttestadStanford$352K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →